What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab: - PMR RR 3.8x N/I vs. P - no diff in GCA risk @RheumNow #ACR24 https://t.co/IF4Gh7Cumd

🔶Clinical Year in Review #ACR24 🔶 Talk By @MHPillingerMD • Review some of the most impactful studies in Rheumatology from the past year! #RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX

The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y

Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely! #ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp

Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor. #ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO

SURPASS trial of bio naïve axSpA at risk of radiographic progression: 1. Presence of syndesmophytes 2. Higher CRP levels 3. Higher ASDAS 4. Higher spinal MRI BME scores Were predictors of spinal progression independent of ttnt Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY

In this systematic review & metaanalyis by Dr. RFarhat et al, tacrolimus whole blood levels decrease in the 1st & 2nd trimesters then increase back to pre-pregnancy levels postpartum. Needs further studies to guide dose adjustment. @RheumNow #ACR24 abs1535 https://t.co/5MovzPJoFc